Swarm Oncology, a biotechnology company specializing in T cell therapies for advanced solid cancers, announced its official launch and the appointment of Martin Olin as chief executive officer.
The company’s proprietary Swarm-T platform leverages immune system priming and advanced ex vivo cell processing to produce large numbers of non-exhausted T cells capable of homing, infiltrating, and killing cancer cells.
Ex vivo cell therapies involve processing a patient’s cells outside the body to enhance their therapeutic potential before reintroducing them. Swarm Oncology’s Swarm-T platform uses the approach to generate large quantities of non-exhausted T cells, primed to target, infiltrate, and eliminate cancer cells effectively.
The approach seeks to overcome the shortcomings of existing therapies, which can fail to generate durable immune responses. Swarm Oncology plans to advance its first therapeutic candidate into clinical trials within the next 12 to 15 months.
Martin Olin, formerly CEO of BerGenBio ASA and Symphogen A/S, brings over 25 years of leadership experience in the biopharma industry to his new role. He expressed enthusiasm for the company’s potential, stating that Swarm Oncology’s platform is designed to deliver T cells with unmatched potency, specificity, and durability to address the high mortality rates associated with solid cancers.
Swarm Oncology has demonstrated the platform’s ability to generate potent T cells even from immunocompromised patients. Backed by Delin Ventures, the company aims to transform cancer treatment by creating therapies capable of achieving long-term remission for patients with advanced metastatic cancers.